Context: Neurotensin (NT), an intestinal peptide released by fat ingestion, promotes lipid absorption; higher circulating NT levels are associated with type 2 diabetes (T2D), obesity, and cardiovascular disease. Whether NT is related to nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) has not been fully investigated.
N onalcoholic fatty liver disease (NAFLD) is a pathological condition characterized by the macrovesicular accumulation of triglycerides within hepatocytes (hepatic steatosis); in a number of cases, necroinflammatory activity and fibrosis coexist [nonalcoholic steatohepatitis (NASH)]; furthermore, cirrhosis and liver failure may occur in 20% to 25% of affected individuals (1, 2) . Nowadays, NAFLD represents the most common cause of chronic liver disease in developed countries (3) , being detectable in 20% to 30% of the general population (4, 5) in almost 75% of patients with type 2 diabetes (T2D) (6, 7) and in up to 90% of obese individuals with T2D (8, 9) . In dysmetabolic conditions, NAFLD worsens inflammatory and metabolic outcomes (10) (11) (12) and is associated with a greater prevalence and severity of microvascular and macrovascular complications in patients with T2D (13) (14) (15) . Indeed, NAFLD is universally recognized as an independent risk factor for cardiovascular mortality (16) . Nowadays, despite the impressively high number of pharmacological interventions proposed, the identification of an effective therapy of NAFLD beyond standard lifestyle measures is still an open issue and represents a major challenge (17) .
Neurotensin (NT), a 13-amino acid peptide mainly secreted by neuroendocrine cells in the small intestine (18) , displays an important role in regulating food ingestion and fat absorption (19) . By doing so, NT influences energy balance and body weight (20) . NT mainly acts as a neurotransmitter in the central nervous system and as a hormone in the periphery, exerting its physiological action by binding the specific NT receptors, NTSR1, NTSR12, and NTSR13 (21, 22) . Experimental evidence has shown that the NT/NTSR1 system is involved in adaptive energy balance (23) (24) (25) . Loss of the leptin action mediated by NT neurons coexpressing the long form of the leptin receptor determines overweight and impairs the ability to appropriately respond to energy deprivation in experimental mice (24) , pointing out a crucial role of NT in mediating, among others, leptin (23) (24) (25) and ghrelin (25) pathways. Indeed, the leptinmediated systems regulating appetite are controlled by NT-expressing neurons (23) . In the periphery, NT influences body weight by controlling macronutrient absorption. Physiology studies have described an acute increase of intestinal NT release immediately after food ingestion, directly associated with meal fat content (26) . In addition, several data have been produced on the role of NT in facilitating lipid digestion and fat absorption in the small intestine (27) (28) (29) . The refined, complex control of energy balance exerted by NT at different levels provides a possible pathophysiological explanation about a correlation between its circulating levels and increased prevalence and incidence of obesityrelated diseases (30, 31) . In particular, within the large cohort of the Malmö Diet and Cancer Study (30) , the fasting concentration of pro-NT, the circulating peptide secreted at equimolar levels to NT, was associated with the incidence of T2D, cardiovascular disease, breast cancer, and total and cardiovascular mortality (30) . The association between pro-NT and incident major cardiovascular events has been confirmed in the Framingham Heart Study Offspring cohort, independently of the presence of traditional cardiovascular risk factors (31) . Very recently, an extensive investigation on a putative causal role of NT in determining aberrant fat accumulation and metabolic diseases has been carried out (29) , showing reduced intestinal fat absorption, along with protection from obesity and NAFLD, in NT-deficient mice fed with a high-fat diet. Furthermore, the same study demonstrated that in humans, higher plasma pro-NT levels were associated with features of insulin resistance and doubled the risk of developing obesity later in life in nonobese individuals.
Despite the strong rationale behind and encouraging evidence from animal models, little is known on circulating pro-NT levels and NAFLD/NASH in humans. Therefore, aims of this study were to investigate the relationship between plasma NT concentration and the presence and severity of NAFLD/NASH in adult obese individuals with or without T2D and to determine clinical correlates of impaired NT levels in this population.
Materials and Methods

Population
For these purposes, we recruited 60 consecutive obese candidates for bariatric surgery referring to the endocrinology and diabetes outpatient clinics of Sapienza University of Rome for preoperative evaluations. The presence of an association between circulating pro-NT levels and NAFLD was further explored in a cohort of individuals (n = 260) referring to the same outpatient clinics for metabolic evaluations, including upper abdomen ultrasonography (US) for assessing the presence of fatty liver. To be eligible for the study, all study participants had to fulfill the following criteria: male and female aged between 20 and 65 years; no history of current or past excessive alcohol drinking, as defined by an average daily consumption of alcohol .30 g/d in men and .20 g/d in women; negative tests for the presence of hepatitis B surface antigen and antibody to hepatitis C virus; absence of history and findings consistent with cirrhosis and other causes of liver diseases (autoimmune hepatitis, hemochromatosis, Wilson disease); and no treatment with drugs known to cause liver steatosis (e.g., corticosteroids, estrogens, methotrexate, tetracycline, calcium channel blockers, or amiodarone). Furthermore, patients belonging to the morbidly obese cohort had a clinical indication for bariatric surgery. All participants underwent a complete workup, including medical history collection, clinical examination, anthropometric measurements, and laboratory tests.
Clinical and laboratory assessment
Weight and height were measured with patients wearing light clothing and no shoes. Body mass index (BMI, kg/m 2 ) was calculated as weight in kilograms divided by height in meters squared. Waist circumference was measured midway between the 12th rib and the iliac crest. Systemic systolic blood pressure and diastolic blood pressure were measured after 5 minutes of rest; three measurements were taken, and the average of the second and third measurements was recorded and used in the analyses. Individuals without a previously formulated diagnosis of diabetes mellitus underwent a standard oral glucose tolerance test measuring blood glucose and insulin at baseline and 30, 60, 90, and 120 minutes after glucose ingestion. A 12-hour overnight fasting blood sample was obtained before surgery for metabolic profiling. Fasting blood glucose (mg/dL), glycosylated hemoglobin (%, mmol/mol), total cholesterol (mg/dL), high-density lipoprotein cholesterol (mg/dL), triglycerides (mg/dL), aspartate aminotransferase (AST, IU/L), alanine aminotransferase (ALT, IU/L), and creatinine (mg/dL) were measured by centralized standard methods. Fasting blood insulin (IU/mL) was measured by radioimmunoassay (ADVIA Insulin Ready Pack 100; Bayer Diagnostics, Milan, Italy), with intra-assay and interassay coefficients of variation ,5%. Low-density lipoprotein cholesterol value was obtained the Friedewald formula.
For our purposes, we measured the circulating concentration of pro-NT in plasma frozen immediately after separation and stored at 280°C. Pro-NT was measured using a chemiluminometric sandwich immunoassay to detect pro-NT amino acids 1 to 117 as described previously (32) . The analytical assay sensitivity (mean relative light units of 10 determinations of sheep serum plus two standard deviations) was 4.8 pmol proNT/L. The interassay (10 assay runs) coefficient of variability was 6.2% at 48 pmol proNT/L and 4.1% at 191 pmol/L. Recovery and dilution was .85% in a measurement range of 25 to 850 pmol/L.
The homeostasis model assessment of insulin resistance and homeostasis model assessment of insulin secretion were calculated as previously described (33) . Diabetes mellitus was defined according to the American Diabetes Association 2009 criteria (34) and metabolic syndrome (MS) by the modified National Cholesterol Education Program Adult Treatment Panel III criteria (35) .
Liver biopsy and histology
Study patients underwent intraoperative liver biopsy during surgery for sleeve gastrectomy. All procedures were conducted in accordance with recommendations set by the American Association for the Study of Liver Diseases (36) . Liver fragments were fixed in buffered formalin for 2 to 4 hours and embedded in paraffin, and sections were cut and stained with hematoxylin and eosin and Masson trichrome stains. A single pathologist (C.D.C.) blinded to patients' medical history and biochemistry performed the overall histological evaluations. A minimum biopsy length of 15 mm or the presence of 10 complete portal tracts was required (37) . Liver biopsy samples were classified based on the presence of NASH by Brunt et al. (38) and graded according to the NAFLD activity score (NAS) (39); fibrosis was quantified on the basis of the NASH Clinical Research Network Scoring System Definition (39).
NAFLD assessment in individuals not candidates for surgery
In individuals who were not candidates for surgery, NAFLD was evaluated through liver US. This was performed using an Esaote (Genoa, Italy) instrument with a convex 3.5-MHz probe by the same operator blinded to laboratory values. Liver steatosis was defined according to Saverymuttu et al. (40) on the basis of abnormally intense, high-level echoes arising from the hepatic parenchyma, liver-kidney difference in echo amplitude, echo penetration into the deep portion of the liver, and clarity of liver blood vessel structure. (38) . NAS was used as a continuous scale for activity assessment, and comparisons between more than two were obtained by a Bonferroni-adjusted analysis of variance test. The predictive value of plasma pro-NT for NAFLD identification was estimated by the area under the receiver operating characteristic curve, with a 95% confidence interval (CI). Multivariate logistic regression models were built to identify determinants of NAFLD (yes/no, dependent variable) in our study population, entering all the variables significantly associated with the bivariate analyses as covariates. Data are shown as mean 6 standard deviation. For all the above, a two-tailed P value ,0.05 was considered significant.
Statistics
To our knowledge, no study has investigated circulating pro-NT levels in relation to NAFLD. Therefore, to confirm the statistical power of this study, we performed a post hoc sample size calculation considering the mean pro-NT concentration in individuals with and without NAFLD, and we calculated that 15 patients per subgroup would be enough to reach the statistical significance with power = 90% and a error = 0.05. For all the above, a P value ,0.05 was considered significant.
The study protocol was reviewed and approved by the Ethics Committee of Policlinico Umberto I, Sapienza University of Rome and conducted in conformance with the Helsinki Declaration. Written consent was obtained from all patients before the study.
Results
Pro-NT and biopsy-proven NAFLD/NASH
Within our study population, 32 of 60 patients (53%) had histological features of NAFLD; clinical and biochemical characteristics of the study population in relation to the presence of NAFLD are shown in Table 1 , along with results from age-, sex-, and BMI-adjusted partial correlation analyses.
Plasma pro-NT levels were significantly higher in patients with NAFLD than in those without NAFLD (183.6 6 81.4 vs 86.7 6 56.8 pmol/L, P , 0.001; Fig. 1A ) and directly correlated with the diagnosis of NASH, severity of steatosis, intrahepatocyte ballooning, and, subsequently, higher NAS and Steatosis Activity Fibrosis score, as shown in Table 2 . In particular, pro-NT levels were significantly higher throughout increasing NAS severity subgroups (P , 0.001; Fig. 1B) , and this association was strongly significant after correcting for sex and age in the partial correlation analysis (r = 0.62, P , 0.001). Among clinical parameters, greater pro-NT levels correlated with age, female sex, T2D, and parameters associated with insulin resistance and impaired glucose metabolism, as detailed in Table 2 . In contrast, no association was found for BMI and waist circumference.
The presence of biopsy-proven NAFLD was associated with female sex (r = 0.31, P = 0.02), higher pro-NT (r = 0.56, P , 0.001), higher ALT (r = 0.30, P = 0.03), and lower AST/ALT (r = -0.37, P = 0.009). In the multivariate logistic regression analysis, higher pro-NT levels were associated with biopsy-proven NAFLD independently from possible confounders (Table 3) . Higher pro-NT concentration predicts the presence of NAFLD, with an area under the receiver operating characteristic curve of 0.836 (95% CI, 0.73 to 0.94, P , 0.001; Fig. 2 ).
Pro-NT and US-detected NAFLD
Of the 260 consecutive individuals undergoing metabolic characterization and liver US, 60% (n = 157) had a diagnosis of NAFLD; patients with NAFLD had significantly higher plasma pro-NT levels than non-NAFLD individuals (190.78 6 116.6 vs 154.3 6 88.9 pmol/L, P = 0.003). Clinical and metabolic characteristics of this study cohort, according to the presence of NAFLD, are shown in Supplemental Data 1. In the bivariate analyses, greater pro-NT levels correlated with the presence of NAFLD (r = 0.19, P = 0.002), T2D (r = 0.25, P = 0.001), and female sex (r = 0.15, P = 0.05), whereas a trend toward a positive association that did not reach statistical significance was observed between higher pro-NT levels and the number of MS components (r = 0.11, P = 0.08). No association was found between pro-NT, age, and indexes of body adiposity, such as BMI and waist circumference (Supplemental Data 2). The multivariate logistic regression analysis confirmed that higher pro-NT correlated with the presence of NAFLD independently from age, sex, presence of T2D, and number of MS components (Supplemental Data 3).
Discussion
This study demonstrates the existence of an association between circulating pro-NT levels and the presence and severity of biopsy-proven NAFLD and NASH in obese adults. The relationship between higher pro-NT and NAFLD was confirmed in a larger population of adults with a diagnosis of fatty liver made with US examination but without signs of severe liver damage, thus reinforcing the evidence obtained in patients evaluated with liver histology.
Recently Li et al. (29) , in an extensive investigation on mechanisms behind the association between higher pro-NT and the development of obesity and cardiometabolic diseases (30, 31), found significantly reduced intestinal fat absorption in NT-deficient mice and protection toward high-fat diet-induced obesity, hepatic steatosis, and insulin resistance in comparison with wild-type mice (29) . As NT-deficient mice (29), NTR3-deficient mice are protected from high-fat diet-induced obesity and fatty liver (41) , indicating that NT-induced hepatic fat accumulation is mediated by both NTR1 and NTR3. In our study, higher pro-NT correlated with T2D and signatures of impaired glucose metabolism and insulin resistance, but not with adiposity per se, in line with previous reports (16) and may determine and worsen insulin resistance, systemic inflammation (10) , and metabolic complications of obesity (11, 12) . Indeed, we observed a linear association between pro-NT, hepatic damage in NASH, and parameters related to glucose metabolism impairment.
A possible weakness of this novel observation can be represented by the limited sample size of the cohort undergoing liver biopsy. However, obtaining samples for liver histology implies the use of invasive procedures, reasonably representing per se a limiting factor for study enrollment.
On the other hand, all the study participants underwent accurate metabolic characterization; the study was monocentric, and all the procedures were performed by the same operator, strengthening the study design and the reliability of our results. Finally, the findings obtained in the main study population have been confirmed in an additional cohort undergoing hepatic US and metabolic phenotyping, reinforcing our results and making them applicable also in individuals with different degrees of body adiposity and nonclinically relevant hepatic damage. Indeed, the association between plasma pro-NT and different measurements of NAFLD broadens the clinical utility of our findings.
Although the cross-sectional design of our study does not allow us to establish a causal nexus between these findings, it is plausible to hypothesize that increased pro-NT levels facilitate the absorption of fatty acids from the small intestine, promoting fat accumulation in specific sites, such as the liver. Thus, NT may lead to NAFLD/NASH in a dose-dependent manner and may act both directly and indirectly-through hepatic fat accumulation-in worsening insulin resistance and the metabolic profile. Gut hormone regulation is currently considered an appealing target for antiobesity treatment (42, 43) ; in this context, our findings are intriguing and may provide the basis for further investigation on novel therapeutic approaches to NAFLD. Moreover, pro-NT may represent a novel biomarker of NAFLD in individuals with and without obesity, with relevant implications in clinical practice. In conclusion, our study demonstrates for the first time, to our knowledge, that pro-NT levels predict the presence of biopsy-proven NAFLD in obese individuals and are associated with insulin resistance and a detrimental metabolic profile. Studies on larger cohorts and longitudinal designs are warranted to investigate the possible role of NT in the development, progression, and prognosis of NAFLD and NASH. The presence of NAFLD is the dependent variable. Pro-NT is considered a continuous variable. Cox and Snell R 2 = 0.412.
